ClinicalTrials.gg
CompletedNCT07272629Updated Jun 23, 2026

A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.

A Phase 1 interventional study of Balinatunfib and Moxifloxacin in Cardiac Repolarization and Healthy Volunteers, sponsored by Sanofi. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a Phase 1, multicenter, randomized, double-blind, double-dummy, single dose, placebo- and positive-controlled, 4-sequence, 4-treatment, 4-period crossover study.

02

Conditions studied

  • Cardiac Repolarization
  • Healthy Volunteers
03

In context

Lead sponsor

Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: Healthy males and/or females aged 18 to 55 (inclusive) at consent signing.
  • Certified healthy based on history, physical exam, vitals, , and labs with no abnormalities.
  • Weight: 50-100 kg (male), 40-90 kg (female); 18-30 kg/m² inclusive.
  • Sex-based eligibility: All males must use effective or remain abstinent and avoid sperm donation for 3 months post-dose. Females must use highly effective contraception, not be pregnant or breastfeeding, and test negative for pregnancy before treatment.

Exclusion criteria

Exclusion Criteria:

  • History of significant systemic diseases (hematologic, renal, endocrine, pulmonary, GI, cardiac, hepatic, psychiatric, neurologic, infectious, allergic; except mild seasonal allergies).
  • abnormalities.
  • Frequent headaches or migraines, and recurrent nausea or vomiting (over twice monthly).
  • Blood donation within 2 months.
  • Symptomatic or significant postural hypotension.
  • Drug or significant allergies, including to study drugs.
  • History of drug/alcohol abuse.
  • Tobacco use within 3 months prior to Day 1.
  • History of /C, TB, or invasive opportunistic infections.
  • within 5 years (except treated non- skin cancer).
  • Adverse reaction to balinatunfib, moxifloxacin, or quinolones.
  • Any medication (except hormonal /HRT) within 14 days or 5× half-life.
  • Biologics within 4 months prior.
  • Vaccines: non-live within 4 weeks, live within 3 months before or during study.
  • Current or recent participation in another interventional study within 30 days.
  • Positive for HBsAg, anti-HBc, anti-, anti-HIV1/2.
  • Positive urine drug screen.
  • Positive alcohol breath test.
  • Positive urine cotinine test.
  • History of long syndrome.
  • Risk factors for TdP.
  • Moxifloxacin .
  • Low potassium (\<3.5 mmol/L).
  • Low magnesium (\<0.7 mmol/L).

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Balinatunfib Treatment A

    Participants will receive a single oral dose of balinatunfib.

    Drug: Balinatunfib · Drug: Placebo

  • Experimental
    Balinatunfib Treatment B

    Participants will receive a single oral dose of balinatunfib.

    Drug: Balinatunfib · Drug: Placebo

  • Active comparator
    Moxifloxacin Treatment C

    Participants will receive a single oral dose of moxifloxacin.

    Drug: Moxifloxacin · Drug: Placebo

  • Placebo comparator
    Placebo Treatment D

    Participants will receive a single oral dose of balinatunfib matching placebo and moxifloxacin matching placebo.

    Drug: Placebo

Interventions

  • Pharmaceutical form: Tablet Route of administration: Oral

    Also known as: SAR441566

  • Pharmaceutical form: Tablet Route of administration: Oral

  • DrugPlacebo

    Pharmaceutical form: Tablet Route of administration: Oral

06

What researchers measure

Primary outcomes

  1. Change from baseline in the QT interval corrected using the Fridericia formula (QTcF) centrally assessed using a semi-automatic reading

    Time frame: Baseline to day 2

Secondary outcomes

  1. Change from baseline in heart rate (HR)

    Time frame: Day 1 to Day 2

  2. Change from baseline in QT interval

    Time frame: Baseline to day 2 of each period

  3. Change from baseline in QT interval corrected using the Bazett formula (QTcB)

    Time frame: Baseline to day 2 of each period

  4. Change from baseline in population specific QT correction (QTcN) interval

    Time frame: Baseline to day 2 of each period

  5. Change from baseline in QRS interval

    Time frame: Baseline to day 2 of each period

  6. Change from baseline in PR interval

    Time frame: Baseline to day 2 of each period

  7. Safety for electrocardiogram (ECG) parameters

    Time frame: Baseline to day 83

  8. Maximum plasma concentration (Cmax) for balinatunfib

    Time frame: Baseline to day 6 of each period

  9. Time to reach the maximum concentration (tmax) for balinatunfib

    Time frame: Baseline to day 6 of each period

  10. Area under the curve (AUC) for balinatunfib

    Time frame: Baseline to day 6 of each period

  11. Maximum plasma concentration (Cmax) for balinatunfib metabolite M8

    Time frame: Baseline to day 6 of each period

  12. Time to reach the maximum concentration (tmax) for balinatunfib metabolite M8

    Time frame: Baseline to day 6 of each period

  13. Area under the curve (AUC) for balinatunfib metabolite M8

    Time frame: Baseline to day 6 of each period

  14. Number of participants experiencing treatment-emergent adverse events (TEAEs) including adverse events of special interest (AESIs) and serious adverse events (SAEs)

    Time frame: Baseline to Day 83

  15. Number of participants with clinical laboratory and vital signs abnormalities (potentially clinically significant abnormality)

    Time frame: Baseline to Day 83

07

Study locations

2 sites
  • Fortrea Clinical Research Unit- Site Number : 8400002
    Dallas, Texas 75247, United States
  • Labcorp Clinical Research- Site Number : 8400001
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2025 to primary completion in May 2026, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2025
First posted
Dec 9, 2025
StartActual
Dec 4, 2025
Primary completionActual
May 28, 2026
CompletionActual
Jun 8, 2026
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07272629
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 9, 2025
Start date
Dec 4, 2025
Primary completion
May 28, 2026
Completion
Jun 8, 2026
Last update
Jun 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Balinatunfib

Start the discussion